Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree and we haven't really seen that in a long time. Once the co pr's something and the vol is weak, it's very easy for them to walk this back down.
I believe MM used this latest PR to pounce once they saw very little increase in vol/interest. They knew right away they could bring this down even further. The key will be once we break the 50 & 200 moving averages. Until then the trend is definitely negative. How low she goes this time is hard to tell before she comes back again.
It is quite amazing and just shows how controlled this stock is at the moment. They want it in this tight range for a reason. Just think back to last year before we had any results from the heart trial, and we hit much higher, almost in the teens. We are in so much better position now and still stuck at a nickel gets frustrating but I also know this will move eventually if the keep on the current path.
I agree with you but far easier to do here in penny land/OTC. Less scrutiny and far less coverage than you would have on the NASDAQ.
I agree. MM's are in full control here. Not letting this thing get away from them. Only will run higher when they are finished covering. This is the problem being in OTC land.
This is deja vu from the month and a half we spent between .02-.03. Seemed like it would never go above .03 and there was a lot of frustration then also. But now our base is twice as high and I believe we are in much better shape.
Wouldn't surprise me if he did. They could land an investor anytime now. That's the sorta news that will change things in my opinion.
Of course there is dilution taking place, and believe me the company wants to move away from this type of financing and get a much better deal, and that will happen I believe in due time. For the time being they realize this is their only avenue at the moment. I believe that will be a HUGE catalyst when they secure alternative financing.
Watching this daily/hourly definitely can be frustrating. Remember the battle between .02-.03 that lasted weeks? Building a solid base here in the .05's and the next run should propel us higher than the last one. Hard to time these things though.
Yep no doubt I agree with you there. By the sounds of it, news is imminent, although I hate to use that word if you know what I mean. Hard to be patient on the OTC since most people are flippers/day traders, and of course the MM's are always in control. But I like where we are at compared to this time last year and it doesn't look like it's heading much lower than .05 which is a good thing.
It had nothing to do with comparing the 2 companies technology, but just to show that they are a stage 1 clinical trial with orphan drug status and only a couple million market cap. So your right not comparing Apples to Apples but more of how the OTC is tough to get a what is a seemingly fair market cap.
Biotech, I just checked my email and Steve had responded with a different company he was referring to. The company's name is Propanc Biopharma. Haven't had the chance to research it obviously, but if you do or anyone else let me know what you think. He used this example in my opinion to show how certain things are not justified in OTC land.
Ok thx for confirming Biotech, as I reached out to Steve again, but he seems to always call me back when I'm unprepared to take notes or have the questions I want to ask....lol
Yeah Biotech I'm not sure because this is the second time he's referred to this company and I didn't even bother to write down the name either time. But for some reason I believe it was a company not in the same field as ENDV, but I will find out because now I'm curious myself.
Outstanding Shares. Puts us @ 16.6 mil market cap.
No problem guys, just trying to contribute.
If anyone is interested, OS is 313.4 million.
I just received a call back from Steve in IR, as I had called him yesterday and he didn't get back to me until just now. They all are very excited at where we are at right now, from the heart trial results, to the acquiring of RGN, to the other pre-clinical trials going on, and finally now they can call themselves a clinical stage biotech company.
They seemed to be dumbfounded/puzzled that the share price/market cap remain so low. He did point out another OTC stock, can't recall the name as I should have wrote it down, but they just got orphan drug status and FDA approval and have only a few million cap!
Dr Collier is at the JP Morgan conference as we speak, in fact he was calling Steve during our call....lol So that's the next big thing is taking financing to the next level, and he's obviously meeting with investors.
One last thing Craig, I did ask him about Cytotronics and he basically said that it's on the backburner at this time. It's costly and takes a lot of time. But this what most of us figured anyways.
In my opinion we should be getting more news soon, or that was my takeaway.
People can take this info as they choose. I know I'll get some haters or people think I make this stuff up. No way to prove either way but I know that some people on here appreciate it so that's why I do it.
I agree but it might be another 2-3 weeks though. Chart is setting up beautifully imo for the next leg up.
Huge to hold the 200 dma. Great set-up imo heading into January, if we manage to stay @ or above .05. Definitely should see at least 1 or 2 PR's in Jan.
Yep no problem. I'm going to reach out to Steve again after the holidays, especially if we don't receive data from the heart trial by then. Taking much longer than anticipated to crunch the numbers, as it sounded like it would be anytime the last time I spoke with him, which is about a month ago.
According to Steve Cytotronics is not dead, but they have nothing new to update us with at this time. And yes you are correct that bad news or if things aren't going well, are generally not pr'd. So interpret the long silence as you wish.
I'm with you Brojazzy, and I feel much better now than ever, especially after the initial results from the heart trial were positive. We are putting in higher lows and forming a solid base in my opinion here in the. 05 - .06 range. News is coming, it's not a matter of if but when. And I believe like Midas that we will push into the .20's on the next run and maybe higher. You also have a Merry Xmas as we wind down 2017 and I'm very much looking to the 1Q of 2018!
I'm just curious as to what you want them to PR at this point, and if they did, how does that help sustain/increase share price??
We know they will release the data numbers from the heart trial as soon as they receive them from the clinic. This is taking longer than expected obviously.
We know they are well underway with the other 3 trials, and that we will not have any sort of updates until they hear back from the trial clinics themselves.
We know there is no new info to share at this time on the Cytotronics platform.
And finally we know from a financing standpoint, that they will continue with this type of dilutive financing, but at some pt that will change hopefully, probably as we get more pre-clinical results in and start actual trials.
While it's tough to sit here and be long when there is no news/catalyst, I don't see how getting an update that would basically say what I just said, would increase share price. In fact, I personally believe it would do just the opposite.
Yep, that's exactly what Steve told me a few weeks ago. If we can just hang in there a little while longer, we have many catalysts coming down the pike over the short-medium term. I like that the sp has stabilized for now in this area, even with the constant dilution that is going on. It's just a matter of time before this breaks out again in my opinion.
When I spoke to Steve he was the one who mentioned the release of the data before I even said anything. So to me it sounded like it could be anytime and was just taking a little bit longer than expected from the clinic. So yes they are going to release the data ASAP.
Haven't heard anything within the last 10 days but last time it sounded like they were close to releasing the data from the trial. Maybe this week or next week at the latest hopefully.
Lol....It would be nice if we get something on the Cytotronics platform soon.
I agree with you and the biggest sigh of relief was that the device worked as planned. Now we just have 2 wait on all the upcoming catalysts and go from there. First one being the data release.
No problem. I don't post a lot, but I do try and contribute when I can. I remember when I first bought ENDV at .08, this was after the huge spike and when it came all the way back down. I watched it then go all the way to under a penny. And I believe at that time the board was completely silent. I realize shortly after that drop to a penny that there was definitely some pumping going on, but it was just nice to see some interest here finally. I get frustrated sometimes here too, watching the sp daily and hoping we get some kinda news. But lately and especially after the pre-clinical results came in, makes me feel much more at ease.
Definitely understandable and your right to not fully trust or take what's being said with a grain of salt on any message board. However, with that being said, I don't pump this stock 24/7 or make statements that look like I have insider info. I'm just an average investor who has contacted Steve from time to time over the past year, and I relay what I've been told, which sometimes is just a mere clarification from prior PR's. I'm 100% positive if anyone else would call Steve, which he never answers but usually always calls back, sometimes it takes a day or 2, would get the exact same info I have shared.
Not to get into a argument or long discussion about PR's, but what if they updated us once a month, and the sp actually went down every single time, because investors realize there is no meat sorta speak. The update in June was pretty informative in my opinion, and I don't see what they could update us on that they haven't either already done so, or they have no new info to share. The histology and cytokine data they figured would be ready in 3 weeks is taking longer than expected.
To be fair, when I did question Steve about Cytotronics, it definitely sounded to me that there was something going on, but I guess not quite enough at this time to share with us. So in my opinion, take it for what it's worth, I don't think it has been shelved or anything like that. Again, I don't have any hard evidence, but I was just going by verbal body language, if there is such a thing....lol
Even though there are some of us on here who are longs, and even some of those have flipped this a few times over the past year, there hasn't been REAL money & EYES on this one just yet. When/if that happens u will see this thing really move. So we are just not quite there yet. But at least things are moving in the right direction, and stuff should be happening in the near future.
I will tend to disagree with you on this one. If they put out constant PR's, with basically nothing in them other than stating the current state of affairs, this will signal a sell-off, as what happened back in June when Collier updated us, basically saying that it will be a little while longer before the heart trial results come out. So we do know for sure that the 3 trials are taking place, and that the data from the heart trial will also be coming out pretty soon. Being somewhat in the dark keeps us from having a major sell-off in my opinion, due to news can hit at anytime. We are very vulnerable to "fluff pr's", and that's what I think they would be interpreted as, otherwise I know they would PR anything pertinent.
They have access to funds but they are obviously dilutive in nature and not necessarily the best option, especially long-term, but for right now they believe they are a necessary evil. So it might be a little harsh to say they don't care at all about sp/mc, but as of this moment they don't have a lot of options, other than giving away the farm sorta speak. All these guys have skin in the game, and of course we know how much Mann has spent in the last year alone.
Yeah I understand where your coming from, and I was just relaying there sentiment that I know many on here don't necessarily agree with. He did say that they are still
an early stage bio company, and that big money investors don't come in until they are further along.
So I spoke to Steve today in IR, and he did tell me that they are still waiting on histology & cytokine data from the trial center, and they will PR them as soon as they get them back. He also reconfirmed to me that the other 3 trials are ongoing, and that they learned things from the heart trial, which they used that knowledge to apply to all the current trials. There is quite a bit to these pre-clinical trials with animals, that most people may not realize what actually goes into one.
I also asked about Cytotronics and if there was anything new to share and it this time he said that there wasn't anything they are willing to share with us.
He did also mention the CEO was in New York, maybe speaking with investors is what I gathered. They would obviously like to get an investor for a good chunk of money, let's say $5-10 mil, but like they've already said at what price does that come with and right now they are not willing to give up that much of the company to do so. He definitely seemed please at the direction the company is headed, and they are not so concerned with market cap/sp, because that will take care of itself in due time when things get further along.
Every day/week that goes by and we at least maintain these levels, brings us closer and closer to getting results from the other 3 trials and other possible catalysts such as financing and FDA status.
I believe these initial interim results definitely raised our market cap to at least 10 million and we should not see the return of a 2-3 million dollar cap when this was trading at a penny. But time will tell and obviously we'll continue to have dilution but it doesn't seem to be that bad.
While I don't know Steve personally, I do like him from a standpoint of our conversations we've had. He seems genuine and has always been professional. He wasn't passing the buck of blame/responsibility per se, but you could tell he was a little frustrated in what seems was not fully in his control if you get what I'm saying. And then he's the one who has to deal with all the questions afterwards. And being the head of IR I guess that's obviously he's resposibilty, and he does deserve some of the blame maybe for not making sure what is pr'd is accurate.